Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: A molecular analysis

Bone Marrow Transplantation

Volumn 39, Issue 3, 2007, Pages 189-191

  Palandri, F ^a   Amabile, M ^a   Rosti, G ^a   Bandini, G ^a   Benedetti, F ^b   Usala, E ^c   Angelucci, E ^c   Tiribelli, M ^d   Fanin, R ^d   Martinelli, G ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; BUSULFAN; CYCLOPHOSPHAMIDE; IMATINIB;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LETTER; LEUKEMIA RELAPSE; MUSCULOSKELETAL PAIN; NEUTROPENIA; PERIORBITAL EDEMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; VARIABLE NUMBER OF TANDEM REPEAT; WHOLE BODY RADIATION;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846611983     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705554     Document Type: Letter

References (10)

1. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
2. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
3. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
4. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
5. Daneschnejad S, Lange T, Mueller C, Musiol S, Niederwieser D. Imatinib for relapsed Philadelphia chromosome positive chronic myeloid leukemia after allogeneic haematopoietic stem cell transplantation [abstract]. Bone Marrow Transplant 2005; 35: P800.
6. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, et al., Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707-1712.
7. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015.
8. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 2474-2486.
9. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
10. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.